Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 3,135 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo solution Clear all
Active, not recruiting Phase 2 Interventional

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

NCT07205900
View directory record Official record
Conditions
Obese, Obesity
Interventions
HM15275, Placebo of HM15275
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Chula Vista, California • Oak Lawn, Illinois • Ames, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 17, 2026, 3:58 PM EDT
Not listed Early Phase 1 Interventional

The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

NCT05995392
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Topical spironolactone ophthalmic solution, 0.005 mg/cc, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Not applicable Interventional Results available

Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older

NCT04421014
View directory record Official record
Conditions
Metabolic Syndrome, Normal Cognition
Interventions
Ketone Ester drink, Placebo: isocaloric dextrose drink
Dietary Supplement
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

NCT06106009
View directory record Official record
Conditions
Healthy
Interventions
PF-07976016, Placebo, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder

NCT05132699
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Stress Disorders, Post-Traumatic
Interventions
Cannabidiol (CBD) oral solution, Placebo, Massed Prolonged Exposure (mPE)
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 17, 2026, 3:58 PM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 17, 2026, 3:58 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071
View directory record Official record
Conditions
Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
eneboparatide, Placebo
Combination Product
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Torrance, California • Denver, Colorado • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 17, 2026, 3:58 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07690371
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
19
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

NCT05421598
View directory record Official record
Conditions
Asthma
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Jose, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544763
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

NCT00586664
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bepreve (bepotastine besilate ophthalmic solution) 1.5%, placebo comparator, Bepotastine Besilate Ophthalmic Solution 1.0%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 17, 2026, 3:58 PM EDT
Active, not recruiting Phase 3 Interventional

Trial to Assess Chelation Therapy in Critical Limb Ischemia

NCT03982693
View directory record Official record
Conditions
Critical Limb Ischemia, Diabetes
Interventions
Edetate Disodium, Placebo
Drug · Other
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 17, 2026, 3:58 PM EDT
Terminated Phase 4 Interventional Results available

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

NCT01100437
View directory record Official record
Conditions
Chronic Pain
Interventions
EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 17, 2026, 3:58 PM EDT
Terminated Phase 2 Interventional Results available

High-Dose Deferoxamine in Intracerebral Hemorrhage

NCT01662895
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 17, 2026, 3:58 PM EDT
Suspended Phase 2 Interventional

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

NCT05067257
View directory record Official record
Conditions
Pain, Intractable, Pain Cancer, Pain
Interventions
Resiniferatoxin, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
La Jolla, California • Gainesville, Florida • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction

NCT01559922
View directory record Official record
Conditions
Atrophic Acne Scar
Interventions
Normal Saline, Artefill
Drug · Device
Lead sponsor
Suneva Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Beverly Hills, California • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 2 Interventional

Interstitial Cystitis

NCT00056251
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
H&P; ECG; Blood tests; voiding diary; Cystoscopy
Procedure
Lead sponsor
ICOS Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
24
States / cities
Anchorage, Alaska • Glendora, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 3:58 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers

NCT07644195
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TRL1068, a human monoclonal antibody
Drug
Lead sponsor
Trellis Bioscience LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 3 Interventional

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial

NCT03374800
View directory record Official record
Conditions
Gastrointestinal Hemorrhage (Clinically Important, Upper)
Interventions
Placebo (0.9% saline), Pantoprazole
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
4,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 2 Interventional

Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis

NCT00447837
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
SPRC-AB01
Drug
Lead sponsor
Naryx Pharma
Industry
Eligibility
16 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
43
States / cities
Hoover, Alabama • Jonesboro, Arkansas • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2008 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

NCT03379675
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
JNJ-53718678 500 mg, JNJ-53718678 80 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Cerritos, California • Chula Vista, California • Garden Grove, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 17, 2026, 3:58 PM EDT
Recruiting Phase 2 Interventional

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

NCT06802081
View directory record Official record
Conditions
Atrial Fibrillation, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 17, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Results available

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

NCT03131167
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Interventions
SHP639 (n=60), Placebo Comparator (n=24)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 17, 2026, 3:58 PM EDT
Terminated Not applicable Interventional Results available

Preemptive Femoral & Lateral Femoral Cutaneous Nerve Blocks for THA Acute Pain

NCT01997567
View directory record Official record
Conditions
Internal Derangement of Hip, Acetabular Labrum Tear
Interventions
Ropivacaine, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 17, 2026, 3:58 PM EDT